1998 

M.B.B.S. 

University of Ibadan 

 

2006

FMCPath.

Hematology 

 

2005

Fellow (BMT)

Bone Marrow Transplantation 

1. 2011. Union for International Cancer Control’s (UICC) ICRETT and University of Chicago’s Global Health Initiative Fellowships to the University of Chicago Medical Center, Chicago, USA.

2. 2011. Interacademy Medical Panel’s (IAMP) Young Physician Leader (YPL) award to the World Health Summit, Berlin, Germany.

3. 2010. International Chronic Myeloid Leukemia Foundation (iCMLf) ERSAP Fellowship to the Istituto di Ematologia Seràgnoli, Ospedale S.Orsola-Malpighi, Bologna, Italy.

4. 2004 – 2005. Clinical Research Fellowship of the University Hospital Hamburg to study Bone Marrow Transplantation. 

1.     Nigerian Medical Association (NMA)
2.     Nigerian Society for Haematology and Blood Transfusion (NSHBT)
3.     Medical and Dental Consultants Association of Nigeria (MDCAN)
4.     African Society for Haematology and Blood Transfusion (AfSHBT)
5.     African Organisation for Research and Training in Cancer (AORTIC)
6.     International Network for Cancer Treatment and Research (INCTR)
7.     Federation of Sickle Cell Clubs of Nigeria
8.     European Group for Blood and Marrow Transplantation (EBMT) 

1. Oyekunle AA, Haferlach T, Kröger N, Klyuchnikov E, Zander AR, Schnittger S, Bacher U. (2011) Molecular Diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia. Adv. Hematology. 2011 (2011), Article ID 154745, (DOI:10.1155/2011/154745).

2. Bacher U, Ocheni S, Schafhausen P, Oyekunle AA, Dierlamm J, Zander AR, Bokemeyer C, Haferlach T, Kröger N. (2011) Unusual course of Myelodysplastic syndrome with presumed familial origin. Acta Haematol. 126(4):234-237 (DOI: 10.1159/000330529)

3. Oyekunle AA, et al. (2011) F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib. Leuk Res. 35(7):e118-20. Epub 2011 Apr 12.

4. Oyekunle AA, et al. (2011) Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol. 126:30-39 (DOI: 10.1159/000323662).

5. Ocheni S, Oyekunle AA, et al. (2011) Second allogeneic stem cell transplantation in a patient with hypoplastic MDS following a primary diagnosis of aplastic anaemia. Acta Haematol. 125:175-178 (DOI: 10.1159/000322609).

6. Oyekunle AA, et al. (2010) Does the ESR-adjusted serum ferritin concentration predict iron deficiency better? J of Med Medical Sc. 1(8):331-335.

7. Oyekunle AA, et al. (2010) H396R, F359V and E255K mutations of the Abl kinase domain in imatinib-resistant Nigerian patients with chronic myeloid leukemia. Afr J Haem Oncol. 1(3):79-83.

8. Salawu L, Oyekunle AA, Durosinmi MA. (2010) Effects of Imatinib mesylate (Glivec) on some circulating immunocytes in a group of Nigerians with chronic myeloid leukaemia: a preliminary study. Afr J Haem Oncol. 1(3):84-88.

9. Ocheni S...Oyekunle AA, et al. (2010) EBV-Associated Malignancies. The Open Infect Dis J. 4:101-12.

10. Oyekunle AA, et al. (2010) Successful pregnancies in a Nigerian patient with chronic myeloid leukaemia on imatinib. Ann Trop Path.1(1):35-39.

11. Bolarinwa RAA...Oyekunle AA, et al. (2009) AIDS-related lymphomas: an emerging problem in Nigeria. Braz J of Infect Dis. 13(5):359-61.

12. Durosinmi MA...Oyekunle AA, et al. (2008) The use of Imatinib mesylate (Glivec) in Nigerian patients with Chronic Myeloid Leukemia. Cellular Ther.

13. Durosinmi MA...Oyekunle AA, Bella AF. (2007) Herpes zoster complicating Imatinib mesylate for gastrointestinal stromal tumour. Singapore Med J. 48(1):e16-e18.

14. Oyekunle AA, et al. (2006) CD34+ selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. Cytotherapy. 8(4):375-380.

15. Oyekunle AA, et al. (2006) Allogeneic stem-cell transplantation in patients with refractory acute leukemia; a long-term follow-up. Bone Marrow Transplant. 37:45–50.